Report includes chapters which deeply display the following deliverable about industry :
• Epinephrine Market Research Objective and Assumption
• Epinephrine Market Purview - Report Description, Executive Summary, and Coherent
Opportunity Map (COM)
• Epinephrine Market Dynamics, Regulations, and Trends Analysis - Market Dynamics,
Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals,
Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Epinephrine Market, By Regions
• Epinephrine Market Competition by Manufacturers including Production, Share, Revenue,
Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Epinephrine Market Manufacturers Profiles/Analysis including Company Basic Information,
Manufacturing Base and Its Competitors.
• Epinephrine Market Manufacturing Cost Analysis including Key Raw Materials and Key
Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Epinephrine Market Forecast including Production, Consumption, Import and Export Forecast
by Type, Applications and Region.
• Research Findings and Conclusion
Market Dynamics
Increasing prevalence of food allergies is a major factor driving epinephrine market growth.
According to a research conducted by the Centers for Disease Control and Prevention (CDC) in
2013, in the U.S., from 1997 to 2011, food allergies among children increased around by 50%.
Moreover, according to the European Academy of Allergy and Clinical Immunology (EAACI),
over 17 million people in Europe were affected by food allergy in 2015. For instance, in
November 2017, Kaléo, Inc. received the FDA approval for its supplemental New Drug
Application (sNDA) for AUVI-Q, the first and only epinephrine auto-injector (EAI) specifically
designed for the treatment of life-threatening allergic reactions, including anaphylaxis, in infants
and small children weighing 16.5 to 33 pounds.